Related Experiment Video

Updated: May 13, 2026

A New Best Practice for Validating Tail Vein Injections in Rat with Near-infrared-Labeled Agents
04:19

A New Best Practice for Validating Tail Vein Injections in Rat with Near-infrared-Labeled Agents

Published on: April 19, 2019

Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases

Heather N Tinsley1, Gary A Piazza

  • 1Department of Biology, Chemistry and Mathematics, University of Montevallo, Station 6480, Montevallo, AL 35115, USA.

Current Colorectal Cancer Reports
|March 6, 2013
PubMed

Insights

Nonsteroidal anti-inflammatory drugs (NSAIDs) show promise for colorectal cancer prevention, but toxicities limit use. New NSAID derivatives targeting cyclic guanosine monophosphate (cGMP) phosphodiesterases (PDEs) offer a safer, effective strategy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) demonstrate chemopreventive effects against colorectal cancer.
  • However, severe toxicities linked to cyclooxygenase (COX) inhibition restrict their long-term application.
  • Anticancer activity of NSAIDs may stem from off-target effects, independent of COX inhibition.

Purpose of the Study:

  • To explore cyclooxygenase (COX)-independent mechanisms for colorectal cancer chemoprevention.
  • To investigate cyclic guanosine monophosphate (cGMP) phosphodiesterases (PDEs) as a novel therapeutic target.
  • To develop novel NSAID derivatives with enhanced cGMP PDE inhibitory activity and reduced COX inhibition.

Main Methods:

  • Chemical modification of sulindac to create new derivatives.
  • Assessment of COX-inhibitory activity of the novel derivatives.
  • Evaluation of cGMP phosphodiesterase (PDE) inhibitory activity of the modified compounds.

Main Results:

  • Developed novel sulindac derivatives lacking significant COX-inhibitory activity.
  • These derivatives exhibit improved inhibitory activity against cyclic guanosine monophosphate (cGMP) phosphodiesterases (PDEs).
  • cGMP signaling is suppressed in cancer cells, and its activation inhibits tumor growth.

Conclusions:

  • Modified NSAIDs targeting cGMP PDEs represent a promising COX-independent strategy for colorectal cancer prevention and treatment.
  • This approach offers a potential alternative to traditional NSAIDs, mitigating associated toxicities.
  • Further development of these derivatives could lead to improved chemopreventive and therapeutic agents.
Keywords:
Colon cancerCyclic guanosine monophosphateNonsteroidal anti-inflammatory drugPhosphodiesteraseSulindac

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...